NCT05137795View on ClinicalTrials.gov

Inhaled ZYESAMI (Aviptadil Acetate) for Treatment of Severe COVID-19

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 15, 2021

Primary Completion Date

June 15, 2022

Study Completion Date

August 15, 2022

Conditions
SARS-CoV 2COVIDARDSALIAcute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)Dyspnea
Interventions
DRUG

ZYESAMI™ (aviptadil acetate)

Inhaled ZYESAMI™ (aviptadil acetate) 100μg 3x daily by mesh nebulizer

DRUG

Placebo

Normal Saline Inhalation

DEVICE

Nebulized administration of ZYESAMI™ or Placebo

Use of 510(k) cleared mesh nebulizer to deliver investigational product

Sponsors
All Listed Sponsors
lead

APR Applied Pharma Research s.a.

OTHER